NDLI: Definition of the “Drug-Angiogenic-Activity-Index” that Allows the Quantification of the Positive and Negative Angiogenic Active Drugs: A Study Based on the Chorioallantoic Membrane Model

Content Provider	Springer Nature Link
Author	Demir, Resit Peros, Georgios Hohenberger, Werner
Copyright Year	2010
Abstract	Since the introduction of the angiogenic therapy by Folkman et al. in the 1970’ies many antiangiogenic drugs were identified. Only few of them are still now in clinical use. Also the Vascular Endothelial Growth Factor (VEGF), the cytokine with the highest angiogenic activity, has been identified. Its antagonist, Bevacizumab, is produced and admitted for the angiogenic therapy in first line for metastatic colorectal cancer. When we look at preclinical studies, they fail of in vivo models that define the “Drug-AngiogenicActivity-Index” of angiogenic or antiangiogenic drugs. This work proposes a possible standardized procedure to define the “Drug Angiogenic Activity Index” by counting the vascular intersections (VIS) on the Chorioallantoic Membrane after drug application. The equation was defined as follows: {ΔVIS[Drug]−ΔVIS[Control]} / Δ VIS[Control]. For VEGF a Drug-Angiogenic-Activity-Index of 0.92 was found and for Bevacizumab a −1. This means almost that double of the naturally angiogenic activity was achieved by VEGF on the Chorioallantoic membrane. A complete blocking of naturally angiogenic activity was observed after Bevacizumabs application. Establishing the “Drug-Angiogenic-Activity-Index” in the preclinical phase will give us an impact of effectivness for the new constructed antiangiogenic drugs like the impact of effectiveness in the cortisone family.
Starting Page	309
Ending Page	313
Page Count	5
File Format	PDF
ISSN	12194956
Journal	Pathology & Oncology Research
Volume Number	17
Issue Number	2
e-ISSN	15322807
Language	English
Publisher	Springer Netherlands
Publisher Date	2011-01-08
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	Angiogenesis Chorioallantoic membrane Drug angiogenic index Antiangiogenic therapy Immunology Cancer Research Biomedicine general Pathology Oncology
Content Type	Text
Resource Type	Article
Subject	Cancer Research Pathology and Forensic Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Definition of the 'Drug-Angiogenic-Activity-Index' that allows the quantification of the positive and negative angiogenic active drugs: a study based on the chorioallantoic membrane model.

Angiogenesis-dependent diseases and angiogenesis therapy

Angiogenesis and Angiogenic Tyrosine Kinase Receptor Expression in Pediatric Brain Tumors

Hypoxia Generates a More Invasive Phenotype of Tumour Cells: An In Vivo Experimental Setup Based on the Chorioallantoic Membrane

Angiogenesis - A putative new approach in glutamine related therapy

Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

HIF-1α effects on angiogenic potential in human small cell lung carcinoma

Shared pathways: Death receptors and cytotoxic drugs in cancer therapy

Angiogenesis Inhibition in Prostate Cancer: An Update

Definition of the “Drug-Angiogenic-Activity-Index” that Allows the Quantification of the Positive and Negative Angiogenic Active Drugs: A Study Based on the Chorioallantoic Membrane Model

Similar Documents

Definition of the 'Drug-Angiogenic-Activity-Index' that allows the quantification of the positive and negative angiogenic active drugs: a study based on the chorioallantoic membrane model.

Angiogenesis-dependent diseases and angiogenesis therapy

Angiogenesis and Angiogenic Tyrosine Kinase Receptor Expression in Pediatric Brain Tumors

Hypoxia Generates a More Invasive Phenotype of Tumour Cells: An In Vivo Experimental Setup Based on the Chorioallantoic Membrane

Angiogenesis - A putative new approach in glutamine related therapy

Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables

HIF-1α effects on angiogenic potential in human small cell lung carcinoma

Shared pathways: Death receptors and cytotoxic drugs in cancer therapy

Angiogenesis Inhibition in Prostate Cancer: An Update

Definition of the “Drug-Angiogenic-Activity-Index” that Allows the Quantification of the Positive and Negative Angiogenic Active Drugs: A Study Based on the Chorioallantoic Membrane Model